1. Kaushik Banerjee
  2. Announcements
  3. Wednesday, 30 September 2015

This new IVB publication is now online in IRIS at the following link:


This document is for national immunization programme managers and immunization partners involved in operational support. Its objectives are:

• To guide the policy discussions and operational aspects of the introduction of rubella vaccine into the routine immunization schedule.

• To provide technical guidance, up-to-date references on global policy, technical justification and strategic issues related to the introduction and provision of rubella vaccine in the routine immunization programme.

Since 2011, WHO has recommended that countries should make use of their accelerated measles control and elimination activities to also tackle the problem of rubella and congenital rubella syndrome (CRS). This document is designed to help countries towards integrating measles and rubella vaccination.

Attachments (1)
Accepted Answer Pending Moderation

Dear Craig and Narayana,

Thank you. I am glad that you found the guidelines helpful.

Craig, you may find some answers to your first comment in the dicument'Principles and considerations for adding a vaccine to a national immunization programme' published in April 2014, available at

http://apps.who.int/iris/bitstream/10665/111548/1/9789241506892_eng.pdf. Regarding your second observation a new document titled "Global Routine Immunization Strategies and Practices (GRISP) a companion document to the Global Vaccine Action Plan (GVAP)" is under development currently.


  1. more than a month ago
  2. Announcements
  3. # 1
Accepted Answer Pending Moderation

Thanks Kaushik,

Congratulations to the whole team - really clear guidance for countries. Thank you.

I had two obervations, which may be beyond the scope of the individual new vaccine guidelines:

1. Acknowledging the financial trade offs between each new vaccine and how this compares with other RMNCH interventions: Many countries have to make choices between the new vaccines on offer and between new vaccine introductions and other interventions they can invest in long term (ie. often using domestic resources after graduating from GAVI support for example). I wonder if each new vaccine intro guideline may benefit from acknowledging this and how an extra spend on rubella may compare with rota / pneumo / HPV and even broader with key essential components of RMNCH programmes. This menu approach or highlighting different interventions have different cost effectiveness (yes I know less than perfect!) may help inform decision makers.

2. Are there any references to how countries can sustainably continue to maintain coverage >80% or >95%:This is a major constraint and any links to key guidelines (eg. Reach Every Community or others) may help make linkages between the new vaccine and RI / systems communities. Good that the document acknowledges the risk of introducing rubella vaccine into weaker systems delivering <80%DTP3 coverage - there are risks. For example it will be interesting to see (and hope!) that PNG, who are introducing MR vaccine this year will be able to reach and surpass 80% coverage.



  1. more than a month ago
  2. Announcements
  3. # 2
Accepted Answer Pending Moderation


Thank you very much sharing detailed document on Rubella vaccination.

  1. more than a month ago
  2. Announcements
  3. # 3
  • 1

There are no replies made for this post yet.
Be one of the first to reply to this post!